BCL-6和BCL-2蛋白在弥漫大B细胞淋巴瘤中的表达及其临床意义  

Expression and clinical significance of BCL-6 and BCL-2 in diffuse large B-cell lymphoma

作　　者：孙冠星[1] 曹祥山[1] 李青[2] 

机构地区：[1]苏州大学附属第三医院常州市第一人民医院血液科,江苏常州213003 [2]苏州大学附属第三医院常州市第一人民医院病理科,江苏常州213003

出　　处：《临床荟萃》2012年第8期652-656,共5页Clinical Focus

摘　　要：目的探讨BCL-6和BCL-2蛋白的表达与弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的临床特征及预后之间的关系。方法应用免疫组织化学染色的方法检测BCL-6和BCL-2两种蛋白在46例DLBCL中的表达,并分析它们与DLBCL的临床特征及预后的关系。结果 BCL-6和BCL-2蛋白的阳性表达率分别为60.9%(28/46)和54.3%(25/46),BCL-6阳性组和BCL-2阴性组患者预后较好。结论 BCL-6和BCL-2的蛋白表达与DLBCL预后有一定相关性,可作为判断DLBCL预后的参考指标。Objective To investigate the relationship between BCL-6 and BCL-2 as well as the clinical features and prognosis of diffuse large B cell lymphoma（DLBCL）. Methods Immunohistochemistry stain was used to determine the expression of BCL-6 and BCL-2. Results Positive rates of BCL-6 and BCL-2 were 60.9%（28/46） and 54.3%（25/46）.BCL-6 positive and BCL-2 negative expression showed a trend to better overall survival（OS） and progression-free survival（PFS）. Conclusion The results suggest significant correlationship among BCL-6,BCL-2 and prognosis.Moreover,BCL-6 and BCL-2 may be the useful prognostic indicators in diffuse large B cell lymphoma.

关 键 词：淋巴瘤 大细胞 弥漫型 原癌基因蛋白质c-bcl-6 原癌基因蛋白c-bcl-2 预后 

分 类 号：R733.41[医药卫生—肿瘤]